Skip to content
Calculator
Guide

Glutathione injections and IV drips

Last updated: October 27, 2026 · 7 min read · By the Grey Peptides Editorial Board

An IV drip in a hospital room, with a nurse out of focus behind it
Photo by RDNE Stock project on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Glutathione is a tripeptide antioxidant the body makes for itself. Taken by mouth it does raise the body's stores: in a six-month trial, levels rose at 250 and 1,000 mg a day and fell back within a month of stopping.
  • For lighter skin, the randomized evidence is for oral and topical glutathione, and it is modest. In 2019 the Philippines regulator said no published trial had tested injectable glutathione for skin lightening; a 2025 review found one small placebo-controlled IV study, with no significant difference, and called IV glutathione contraindicated. The US FDA has approved no injectable skin lightener.
  • IV glutathione drips are under active FDA investigation. On August 27, 2026, FDA said at least 30 people had adverse events after IV glutathione made from dietary-supplement-grade ingredient, and compounded glutathione vials were recalled in September 2026.
  • Athletes face a separate rule: WADA prohibits IV infusions or injections of more than 100 mL in 12 hours, except in hospital treatment, surgery or clinical diagnostic investigations, whatever the bag contains.

What glutathione is

Glutathione Low is a tripeptide, a chain of three amino acids, that the body makes for itself and uses as an antioxidant 1. Our glutathione entry grades the evidence for its popular uses. It reaches people three ways: as an oral supplement, in creams, and as an injection or IV drip; the IV glutathione in FDA's 2026 alert was made by compounding pharmacies 2.

Does it work by mouth?

Whether glutathione taken by mouth reaches the body has been questioned because of its limited absorption 3. A six-month randomized trial in 54 non-smoking adults tested that directly, giving 250 or 1,000 mg a day or placebo 4. Glutathione levels in blood rose at both doses at one, three and six months. On the higher dose, levels in red blood cells, plasma and lymphocytes were 30 to 35% higher at six months, and in cells from the inside of the cheek 260% higher; on the lower dose, blood and red-cell levels rose 17% and 29% 4. The levels returned to baseline within a month of stopping, and a marker of oxidative stress improved in both dose groups 4.

So for those doses, oral glutathione does raise the body's own levels. What the trial did not show is that higher levels change any health outcome: it measured glutathione and an oxidation marker, not illness or wellbeing.

Skin lightening: what the trials show

Glutathione is sold widely as a skin lightener, and the oral and topical forms have been tested. In a 2012 randomized trial, 60 medical students took 500 mg a day or placebo for four weeks; a melanin index fell at all six measured sites on glutathione, but the difference from placebo was significant at only two, the face and a sun-exposed forearm 5. A 2019 systematic review found that oral glutathione at 500 mg a day and a 2% oxidized-glutathione cream could lighten sun-exposed skin, with no difference on sun-protected skin and some non-serious side effects, but called the evidence inconclusive because of study quality and inconsistent findings 3. A 2025 systematic review counted five randomized trials and one open study of oral glutathione at 250 to 500 mg a day reporting a significant reduction in the melanin index compared with placebo 6. These are small, short trials of a measured skin index, not of lasting change in skin colour.

The injectable form is where the evidence runs out. In its 2019 advisory, the Philippines Food and Drug Administration said no published clinical trial had evaluated injectable glutathione for skin lightening, that it had approved injectable glutathione only as an add-on in cisplatin chemotherapy, and that possible side effects included toxic effects on the liver, kidneys and nervous system 7; a 2016 review notes that adverse effects of IV glutathione prompted that warning 8. The 2025 review found only one placebo-controlled study of IV glutathione, in which 6 of 16 treated people improved against 3 on placebo, a difference that was not significant, and concluded that IV glutathione is contraindicated because of lack of efficacy and side effects 6. In the US, FDA says it has approved no injectable drug for skin whitening or lightening. It warns that such products, which can contain glutathione, vitamin C, collagen Medium and even human placenta, may cause serious harm, and records that in 2017 a federal judge ordered a New Jersey company that sold injectable skin whiteners to stop selling and recall some of its products 9.

IV drips: an active FDA investigation

The most urgent news concerns the drips themselves. On August 27, 2026, FDA said it was aware of at least 30 patients who had adverse events after receiving IV glutathione, alone or with other ingredients 2. The glutathione had been labelled dietary supplement grade, which FDA says is not an appropriate ingredient for injectable drugs, because material made for supplements can carry contaminants, including endotoxins, that are harmful when injected 2. The reported events included fever, chills, pain, dizziness, signs of shock and sepsis-like symptoms, some leading to hospitalization, and FDA said it continued to receive reports and was actively investigating 2.

Recalls followed; FDA's alert already noted two Texas pharmacies recalling glutathione injectables for elevated endotoxin 2. In September 2026, a Houston compounding pharmacy recalled compounded glutathione vials, along with multi-ingredient vials sold as Myers' Cocktail and Tri-Immune Boost, saying they had been compounded with a glutathione ingredient containing elevated endotoxin, and reported nine complaints of fever, chills and similar symptoms 10. CDC, which counted more than 25 people sickened in at least four states, lists four FDA recall notices for elevated endotoxin 11. This has happened before: in February 2019 FDA warned compounders about a glutathione powder supplied to about 100 compounders in 30 states, after seven patients had adverse events, one of them hospitalised after an intravenous injection; FDA said high endotoxin levels may have contributed 12.

The problem FDA describes is the grade of the ingredient, not glutathione itself. If you are offered a glutathione drip, ask which pharmacy compounded it and what grade of glutathione it used; our questions to ask a peptide clinic cover the rest.

Beyond skin: Parkinson's disease

Glutathione has also been tested in Parkinson's disease. In a 2009 pilot trial, 21 people with Parkinson's received 1,400 mg of IV glutathione or placebo three times a week for four weeks; it was well tolerated, but there was no significant difference in symptom scores; the authors called a mild symptomatic effect possible and in need of a larger study 13. A 2017 trial of glutathione sprayed into the nose, in 45 people, found that every group improved, placebo included, and neither dose was better than placebo; one participant on the higher dose developed cardiomyopathy 14.

Legal status and sport

In the US, glutathione is sold as a dietary supplement and compounded by pharmacies. As of October 27, 2026, it sits in Category 1, the substances under evaluation, on FDA's interim list of bulk substances for 503A compounding, last updated May 14, 2026 15; our guide to FDA's categories explains what that allows. Category 1 says nothing about quality: the August 2026 alert concerns injectables made with the wrong grade of ingredient 2.

For athletes, the route matters more than the substance. WADA's 2026 Prohibited List bans intravenous infusions or injections of more than a total of 100 mL per 12-hour period, except those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations 16.

Frequently asked questions

Does oral glutathione work?

It raises the body's levels. In a six-month randomized trial, 250 or 1,000 mg a day increased glutathione in blood and cells, and levels fell back within a month of stopping. Whether that changes health outcomes was not tested.

Do glutathione injections lighten skin?

The randomized evidence for skin lightening is for oral and topical glutathione, and it is modest. In 2019 the Philippines FDA said no published trial had evaluated injectable glutathione for skin lightening; a 2025 review found one small placebo-controlled IV study with no significant difference and called IV glutathione contraindicated. The US FDA has approved no injectable skin lightener.

Are glutathione IV drips safe?

FDA is investigating. On August 27, 2026 it reported at least 30 patients with adverse events, including shock-like and sepsis-like symptoms, after IV glutathione made from dietary-supplement-grade ingredient, and compounded glutathione vials were recalled in August and September 2026.

Is glutathione legal to compound?

Yes, under FDA's interim policy: as of October 27, 2026 it is in Category 1 of the 503A bulk substances list, last updated May 14, 2026. FDA says injectables must not be made from dietary-supplement-grade ingredient.

Is a glutathione drip banned in sport?

The infusion is, if it is large enough. WADA's 2026 list bans IV infusions or injections of more than 100 mL per 12 hours, except those legitimately received in hospital treatment, surgery or clinical diagnostic investigations, whatever they contain.

Sources

  1. Narayanankutty, A., Job, J. T., Narayanankutty, V. (2019). Glutathione, an Antioxidant Tripeptide: Dual Roles in Carcinogenesis and Chemoprevention. Curr Protein Pept Sci, 20(9), 907-917. PMID: 30727890
  2. US Food and Drug Administration. FDA reminds compounders not to use dietary supplement grade glutathione for injectables, August 27, 2026 (content current as of August 27, 2026): at least 30 patients; compounded by different compounding pharmacies; two Texas pharmacies' recalls. Read October 27, 2026. FDA
  3. Dilokthornsakul, W., Dhippayom, T., Dilokthornsakul, P. (2019). The clinical effect of glutathione on skin color and other related skin conditions: A systematic review. J Cosmet Dermatol, 18(3), 728-737. PMID: 30895708
  4. Richie, J. P., Nichenametla, S., Neidig, W., et al. (2015). Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr, 54(2), 251-63. PMID: 24791752
  5. Arjinpathana, N., Asawanonda, P. (2012). Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat, 23(2), 97-102. PMID: 20524875
  6. Sarkar, R., Yadav, V., Yadav, T., et al. (2025). Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol, 64(6), 992-1004. PMID: 39444151
  7. Food and Drug Administration Philippines. FDA Advisory No. 2019-182: Unsafe use of glutathione as skin lightening agent, 2019; read October 2, 2026, and on October 27, 2026 as quoted by GMA News (July 8, 2019): no published clinical trials of injectable glutathione for skin lightening; approved as an adjunct in cisplatin chemotherapy; may damage the liver, kidney and nervous system.
  8. Sonthalia, S., Daulatabad, D., Sarkar, R. (2016). Glutathione as a skin whitening agent: Facts, myths, evidence and controversies. Indian J Dermatol Venereol Leprol, 82(3), 262-72. PMID: 27088927
  9. US Food and Drug Administration. Injectable Skin Lightening and Skin Bleaching Products May Be Unsafe, consumer update, with its update of September 26, 2017 (read October 27, 2026 in FDA's Tagalog edition, whose update note is in English; the English page did not load that day).
  10. US Food and Drug Administration. Company announcement: nationwide recall of compounded glutathione 200 mg/mL, Myers' Cocktail and Tri-Immune Boost vials due to elevated endotoxin levels (Houston, Texas; company announcement September 11, FDA publish date September 13, 2026); read October 27, 2026.
  11. Centers for Disease Control and Prevention. Adverse Events Linked to Injectable Glutathione Compounded with Dietary Supplement Grade Ingredient: Current Situation (updated September 2026): over 25 people sick in at least four states; four FDA recall notices. Read October 27, 2026. CDC
  12. US Food and Drug Administration. Warning to compounders not to use one supplier's glutathione to compound sterile drugs, February 1, 2019: seven patients, one hospitalised; about 100 compounders in 30 states; potential endotoxins. Read October 27, 2026.
  13. Hauser, R. A., Lyons, K. E., McClain, T., et al. (2009). Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord, 24(7), 979-83. PMID: 19230029
  14. Mischley, L. K., Lau, R. C., Shankland, E. G., et al. (2017). Phase IIb Study of Intranasal Glutathione in Parkinson's Disease. J Parkinsons Dis, 7(2), 289-299. PMID: 28436395
  15. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list), updated May 14, 2026; glutathione listed in Category 1; read October 27, 2026. FDA
  16. World Anti-Doping Agency. The 2026 Prohibited List, method M2.2 (intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period, except those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations); read October 27, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead